Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Feb 17;11(1):3971.
doi: 10.1038/s41598-021-83025-2.

Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy

Himanshu Bansal  1 , Jerry Leon  2 , Jeremy L Pont  3 , David A Wilson  3 , Anupama Bansal  4 , Diwaker Agarwal  5 , Iustin Preoteasa  6
Affiliations
Clinical Trial

Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy

Himanshu Bansal et al. Sci Rep. .

Erratum in

Abstract

Despite encouraging results reported with regards to Platelet-rich plasma (PRP) application in osteoarthritis (OA) knee, still critical issues like conclusive structural evidence of its efficacy, standard dose and good manual method of preparation to obtain high yield remains unanswered. Present study is an attempt to optimise the dose and concentration of therapeutic PRP and its correlation with structural, physiologic efficacy with a new manual method of PRP preparation. A total of one hundred and fifty patients were randomized to receive either PRP (10 billion platelets) or hyaluronic acid (HA; 4 ml; 75 patients in each group) and followed up till 1 year. An addition of filtration step with 1 µm filter in manual PRP processing improved platelet recovery upto 90%. Significant improvements in WOMAC (51.94 ± 7.35 vs. 57.33 ± 8.92; P < 0.001), IKDC scores (62.8 ± 6.24 vs 52.7 ± 6.39; P < 0.001), 6-min pain free walking distance (+ 120 vs. + 4; P < 0.001) persisted in PRP compared to HA group at 1 year. Significant decline IL-6 and TNF-α levels observed in PRP group (P < 0.05) compared to HA at 1 month. Study demonstrated that an absolute count of 10 billion platelets is crucial in a PRP formulation to have long sustained chondroprotective effect upto one year in moderate knee OA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flowchart of the clinical trial: Screening, assessment, treatment allocation and follow-up of patients with OA. n number of patients.
Figure 2
Figure 2
Graphical representation of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score of patients in PRP and control groups over 1 Year (a) composite scores, (b) pain score, (c) stiffness score, (d) physical function score (e) Graphical representation of IKDC score.
Figure 3
Figure 3
Evaluation of articular cartilage thickness using MRI after one year of PRP treatment in patient with grade 2 and grade 3 OA knee.
Figure 4
Figure 4
Level of cytokines IL6, IL8 and TNF-α in PRP and HA group.
See this image and copyright information in PMC

References

    1. Messina OD, et al. Nutrition, osteoarthritis and cartilage metabolism. Aging Clin. Exp. Res. 2019;31:807–813. doi: 10.1007/s40520-019-01191-w. - DOI - PubMed
    1. Zhang W, et al. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res. 2016;4:1–4. - PMC - PubMed
    1. Dzobo K, et al. Advances in regenerative medicine and tissue engineering: Innovation and transformation of medicine. Stem Cells Int. 2018;2018:2495848. doi: 10.1155/2018/2495848. - DOI - PMC - PubMed
    1. Do Amaral RJFC, et al. Platelet-rich plasma obtained with different anticoagulants and their effect on platelet numbers and mesenchymal stromal cells behaviour in vitro. Stem Cells Int. 2016;2016:7414036. doi: 10.1155/2016/7414036. - DOI - PMC - PubMed
    1. Halpern BC, et al. The role of platelet-rich plasma in inducing musculoskeletal tissue healing. HSS J. 2012;8:137–145. doi: 10.1007/s11420-011-9239-7. - DOI - PMC - PubMed

Publication types

Substances